HIV is adept at avoiding naturally generated T cell responses; therefore, there is a need to develop HIV-specific T cells with greater potency for use in HIV cure strategies. Starting with a CD4-based chimeric antigen receptor (CAR) that was previously used without toxicity in clinical trials, we op…
Resources by Therapeutic Area
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor
PLOS Pathogens | October 12, 2017
JCI Insight |August 17, 2017
Promising therapeutic approaches for eradicating HIV include transcriptional activation of provirus from latently infected cells using latency-reversing agents (LRAs) and immune-mediated clearance to purge reservoirs. Accurate detection of cells capable of producing viral antigens and virions, and t…
American Journal of Respiratory and Critical Care Medicine | May 2017
Poster Presentation, American Thoracic Society Conference 2017 A.26 Diagnosis and Treatment of Tuberculosis, Poster Session: May 21, 2017
Current AIDS/HIV Report | April 11, 2017
The development and evaluation of strategies for HIV remission rely upon our ability to accurately and precisely quantify the size of the remaining viral reservoir.
Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab
AIDS | April 24, 2017
So far, two case reports involving HIV-infected patients with melanoma treated with ICIs have shown encouraging safety results but distinct viral effects.